TARA.US Protara Therapeutics Inc

Healthcare Biotechnology USA Stocks
2.32 USD
Close of Nov 18, 2026
2.09 7.82
Market cap
USD 143M
P/E
-
P/B
1.04x
ROE
-57.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is TARA.US undervalued?

Graham number

The Graham number of Protara Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Protara Therapeutics Inc fundamental analysis

No fundamental analysis for Protara Therapeutics Inc yet.

Protara Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Protara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for pa…

Full company profile